Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06913023 on ClinicalTrials.gov · last registry update 2026-09-16

Registered but not yet open, with 37 participants planned. Due to report 30 June 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: 2-hour OGTT. Sponsors move these dates routinely; any movement since this site started watching is listed below. The registry entry has been edited 2 times since then.

Status: NOT_YET_RECRUITING
Phase: P2/P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University Health Network, Toronto
Sponsor type: Other
Enrollment: 37
Started: 2026-09-05
Primary completion: 2029-06-30 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-16	Reporting date moved	2027-11-30 → 2029-06-30 19 months later
2026-09-16	Enrollment changed	74 → 37 (-37) participants

Primary outcome

2-hour OGTT

Conditions studied

Kidney Transplant Recipient

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.